Show simple item record

dc.contributor.authorZoppo, Christopher T
dc.contributor.authorEpshtein, Mark
dc.contributor.authorGounis, Matthew J
dc.contributor.authorAnagnostakou, Vania
dc.contributor.authorKing, Robert M
dc.date.accessioned2023-08-21T14:50:21Z
dc.date.available2023-08-21T14:50:21Z
dc.date.issued2023-07-04
dc.identifier.citationZoppo CT, Epshtein M, Gounis MJ, Anagnostakou V, King RM. Longitudinal healing flow diverting stents with phosphorylcholine surface modification. J Neurointerv Surg. 2023 Jul 4:jnis-2023-020500. doi: 10.1136/jnis-2023-020500. Epub ahead of print. PMID: 37402572.en_US
dc.identifier.eissn1759-8486
dc.identifier.doi10.1136/jnis-2023-020500en_US
dc.identifier.pmid37402572
dc.identifier.urihttp://hdl.handle.net/20.500.14038/52448
dc.description.abstractBackground: Flow diversion has become a standard treatment for cerebral aneurysms. However, major drawbacks include the need for dual antiplatelet therapy after implant and delayed complete occlusion of the aneurysm, which occurs when new tissue growth excludes the aneurysm from the parent artery. Biomimetic surface modifications such as the phosphorylcholine polymer (Shield surface modification) represent major advances in reducing thrombogenicity of these devices. However, in vitro studies have raised concerns that this modification may also delay endothelialization of flow diverters. Methods: Bare metal Pipeline, Pipeline Shield, and Vantage with Shield devices were implanted in the common carotid arteries (CCAs) of 10 rabbits (two in the left CCA, one in the right CCA). Following implant and at 5, 10, 15, and 30 days, the devices were imaged with high-frequency optical coherence tomography and conventional angiography to evaluate tissue growth. At 30 days the devices were explanted and their endothelial growth was assessed with scanning electron microscopy (SEM) at five locations along their length using a semi-quantitative score. Results: The average tissue growth thickness (ATGT) was not different between the three devices. Neointima was apparent at 5 days and all devices demonstrated similar ATGT at each time point. On SEM, no difference was found in the endothelium scores between the device types. Conclusion: In vivo, neither the Shield surface modification nor the device design (Vantage) altered the longitudinal healing of the flow diverter.en_US
dc.language.isoenen_US
dc.relation.ispartofJournal of NeuroInterventional Surgeryen_US
dc.relation.urlhttps://doi.org/10.1136/jnis-2023-020500en_US
dc.rights© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.en_US
dc.subjectAneurysmen_US
dc.subjectArteryen_US
dc.subjectDeviceen_US
dc.subjectFlow Diverteren_US
dc.subjectVessel Wallen_US
dc.titleLongitudinal healing flow diverting stents with phosphorylcholine surface modificationen_US
dc.typeJournal Articleen_US
dc.source.journaltitleJournal of neurointerventional surgery
dc.source.countryEngland
dc.identifier.journalJournal of neurointerventional surgery
dc.contributor.departmentRadiologyen_US
dc.contributor.departmentT.H. Chan School of Medicineen_US
dc.contributor.studentChristopher Zoppo


This item appears in the following Collection(s)

Show simple item record